Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News CEL-SCI Corp CVM

Healthcare Biotechnology
CEL-SCI Corporation is a clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system. The Company is focused on the development of product candidates and technologies, such as Multikine, an investigational immunotherapy under development for the potential treatment of certain head and neck... see more

Recent & Breaking News (NYSEAM:CVM)

15 Biggest Mid-Day Losers For Friday

Benzinga.com  December 2, 2016

Mid-Day Market Update: Smith & Wesson Declines On Weak Forecast; Envision Healthcare Shares Spike Higher

Benzinga.com  December 2, 2016

Mid-Morning Market Update: Markets Mixed; Big Lots Earnings Beat Estimates

Benzinga.com  December 2, 2016

CEL-SCI Announces Pricing of $4.25 Million Public Offering of Common Stock and Warrants

Business Wire December 2, 2016

CEL-SCI Announces Proposed Public Offering of Common Stock and Warrants

Business Wire December 1, 2016

CEL-SCI Submits Response to FDA in Connection with Partial Clinical Hold on Phase 3 Clinical Trial

Business Wire November 21, 2016

CEL-SCI Reports Preclinical Data Showing LEAPS Vaccine is Successful in Treating Rheumatoid Arthritis

Business Wire November 14, 2016

Research Reports Initiation on Biotech Stocks -- Spectrum Pharma, Pain Therapeutics, CoLucid Pharma, and CEL-SCI

PR Newswire October 28, 2016

CEL-SCI Provides Update on Partial Clinical Hold on Phase 3 Clinical Trial

Business Wire October 21, 2016

CEL-SCI Reports Clinical Hold on Head and Neck Cancer Study

Business Wire September 26, 2016

IIROC Trading Resumption - CVM

Canada NewsWire September 26, 2016

IIROC Trade Resumption - CVR Medical Corp.

Newsfile September 26, 2016

SEC Charges CEO and Boiler Room Operator With Fraud

Newsfile September 26, 2016

CEL-SCI Announces Resignation of its Founder for Health Reasons

Business Wire September 6, 2016

CEL-SCI Reports Monthly Patient Enrollment in August for Its Phase 3 Head and Neck Cancer Trial

Business Wire September 2, 2016

CEL-SCI Announces the Closing of Its $5 Million Registered Direct Offering

Business Wire August 29, 2016

CEL-SCI Announces $5 Million Registered Direct Offering

Business Wire August 23, 2016

CEL-SCI Corporation Reports Third Quarter Fiscal Year 2016 Financial Results

Business Wire August 10, 2016

CEL-SCI Reports Monthly Patient Enrollment in July for Its Phase 3 Head and Neck Cancer Trial

Business Wire August 1, 2016

CEL-SCI Granted European Patent for Multikine Cancer Immunotherapy in Combination with Radiation and/or Chemotherapy

Business Wire July 11, 2016